Abstract
Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.
Original language | English |
---|---|
Pages (from-to) | 443-448 |
Number of pages | 6 |
Journal | Future Oncology |
Volume | 14 |
Issue number | 5 |
DOIs | |
Publication status | Published - Feb 1 2018 |
Keywords
- abiraterone acetate
- cardiovascular risk factors
- frail patients
- metastatic castration-resistant prostate cancer
- multidisciplinary management
- prospective study
- safety
ASJC Scopus subject areas
- Oncology
- Cancer Research